HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective

scientific article

HIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective is …
instance of (P31):
review articleQ7318358
scholarly articleQ13442814

External links are
P356DOI10.1186/1471-2334-14-S6-S13
P932PMC publication ID4178534
P698PubMed publication ID25253564

P50authorOle KirkQ102213445
Amanda MocroftQ47006497
Jürgen RockstrohQ47006499
Daniel GrintQ56334582
Jens LundgrenQ42325404
P2093author name stringLars Peters
P2860cites workReasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping Due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C CoinfectionQ57877746
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?Q81473082
Predicting cirrhosis risk based on the level of circulating hepatitis B viral loadQ46985831
Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?Q51070641
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis CQ57877639
Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patientsQ28274666
Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA.Q33648600
Characteristics and treatment outcomes among HIV-infected individuals in the Australian Trial in Acute Hepatitis CQ33955516
Hyaluronic acid levels predict risk of hepatic encephalopathy and liver-related death in HIV/viral hepatitis coinfected patientsQ34749550
The rapid evolution of treatment strategies for hepatitis C.Q38204657
Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infectionQ39526550
A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA studyQ39759946
Hepatitis C seroconversions in HIV infection across Europe: which regions and patient groups are affected?Q41332840
High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearanceQ42215928
Increased incidence of antiretroviral drug discontinuation among patients with viremic hepatitis C virus coinfection and high hyaluronic acid, a marker of liver fibrosisQ42230942
Hepatitis C viral load, genotype 3 and interleukin-28B CC genotype predict mortality in HIV and hepatitis C-coinfected individuals.Q42980077
Spontaneous viral clearance, viral load, and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in EuropeQ42981324
Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patientsQ42982110
Hepatitis C virus coinfection does not influence the CD4 cell recovery in HIV-1-infected patients with maximum virologic suppressionQ42986831
Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals-experience from 2 large German networks on the study of acute HCV infectionQ42988737
Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfected individuals treated with combination antiretroviral therapyQ42990589
Lack of association of hepatitis C virus load and genotype with risk of end-stage liver disease in patients with human immunodeficiency virus coinfectionQ43034920
Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trialQ43040301
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?Q45422165
Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapyQ45424761
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P407language of work or nameEnglishQ1860
P921main subjectArgentinaQ414
IsraelQ801
hepatitis CQ154869
infectionQ166231
human immunodeficiency virus infectious diseaseQ18556697
RNA virus infectious diseaseQ18967413
Retroviridae infectious diseaseQ19000689
P5008on focus list of Wikimedia projectScienceSourceQ55439927
P304page(s)S13
P577publication date2014-09-19
P1433published inBMC Infectious DiseasesQ15759919
P1476titleHIV and hepatitis C co-infection in Europe, Israel and Argentina: a EuroSIDA perspective
P478volume14 Suppl 6

Reverse relations

cites work (P2860)
Q61958644Accelerating the elimination of viral hepatitis: a Lancet Gastroenterology & Hepatology Commission
Q45255359Editorial: direct-acting anti-virals - not the be-all and end-all in HIV/HCV co-infection
Q40481513Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.
Q38950820European AIDS Clinical Society Standard of Care meeting on HIV and related coinfections: The Rome Statements
Q92518090Hepatitis B and C virus infection among HIV patients within the public and private healthcare systems in Chile: A cross-sectional serosurvey
Q55411140Hepatitis C coinfection adversely affects the life expectancy of people living with HIV in northwestern Poland.
Q40671938Human Immunodeficiency Virus/Hepatitis C Virus Coinfection in Spain: Prevalence and Patient Characteristics.
Q90644707Life-Expectancy Disparities Among Adults With HIV in the United States and Canada: The Impact of a Reduction in Drug- and Alcohol-Related Deaths Using the Lives Saved Simulation Model
Q40355278Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna

Search more.